NEW YORK (GenomeWeb) – Trovagene said today that it is initiating a new multi-phased research collaboration with the University of Michigan Comprehensive Cancer Center in which Michigan investigators will use the company's KRAS ctDNA test and assess its utility in detecting early pancreatic cancers and monitoring patients as they undergo therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.